Search results
Results from the WOW.Com Content Network
The authors came to the conclusion that no further trials of hydroxychloroquine or chloroquine for treatment of COVID-19 should be carried out. [57] On 26 April 2021, in its amended clinical management protocol for COVID-19, the Indian Ministry of Health lists hydroxychloroquine for use in patients during the early course of the disease. [22]
Initial use of ECMO in COVID-19 patients from China early in the pandemic suggested poor outcomes, with less than 90% mortality. [83] In March 2020, the ELSO registry began collecting data on the worldwide use of ECMO for patients with COVID-19 and reporting this data on the ELSO website in real time.
In 2020, then-President Donald Trump said he had been taking hydroxychloroquine to prevent a COVID-19 infection, despite warnings by the U.S. Food and Drug Administration over its effectiveness.
The Randomised Evaluation of COVID-19 Therapy (RECOVERY Trial) [1] is a large-enrollment clinical trial of possible treatments for people in the United Kingdom admitted to hospital with severe COVID-19 infection. [2] [3] [4] The trial was later expanded to Indonesia, Nepal and Vietnam. [5]
Around the globe, a new strain of COVID-19 is spreading exponentially. The COVID-19 XEC variant is derived from Omicron strains KS.1.1 and KP.3.3, says Dr. Francesca Torriani, MD, an infectious ...
The Infectious Diseases Society of America (IDSA) guideline panel suggests the use of glucocorticoids for patients with severe COVID-19; where severe is defined as patients with oxygen saturation (SpO 2) ≤94% on room air, and those who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). [177]
During Covid-19, there has been an increase in relatively inexpensive UV light-emitting gizmos that claim to eradicate the novel coronavirus from your cell phone and surgical masks. But are they ...
Bebtelovimab is a neutralizing human immunoglobulin G1 (IgG1) monoclonal antibody, isolated from a patient who has recovered from the Coronavirus disease 2019 (COVID-19), directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19.